Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024. The company, which utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in locating chronic low back pain sources, will be presenting at 4:00 PM ET.
Investors interested in attending the presentation can access it via the provided webcast link. Additionally, there's an opportunity for one-on-one meetings with Aclarion's management team, which can be arranged through the Investor Summit Group's registration process.
Aclarion (Nasdaq: ACON), un'azienda di tecnologia sanitaria specializzata nella diagnosi del dolore cronico alla schiena, ha annunciato la sua partecipazione al prossimo Virtual Investor Summit in programma il 20 agosto 2024. L'azienda, che utilizza biomarcatori e algoritmi proprietari di intelligenza aumentata per aiutare i medici a individuare le fonti del dolore cronico alla schiena, presenterà a 16:00 ET.
Gli investitori interessati a partecipare alla presentazione possono accedervi tramite il link per il webcast fornito. Inoltre, c'è la possibilità di organizzare incontri individuali con il team di gestione di Aclarion, che possono essere prenotati attraverso il processo di registrazione del gruppo Investor Summit.
Aclarion (Nasdaq: ACON), una empresa de tecnología sanitaria especializada en el diagnóstico del dolor lumbar crónico, ha anunciado su participación en el próximo Virtual Investor Summit programado para el 20 de agosto de 2024. La empresa, que utiliza biomarcadores y algoritmos de inteligencia aumentada propios para ayudar a los médicos a localizar las fuentes del dolor lumbar crónico, presentará a las 4:00 PM ET.
Los inversores interesados en asistir a la presentación pueden acceder a ella a través del enlace al webcast proporcionado. Además, hay una oportunidad para reuniones individuales con el equipo de gestión de Aclarion, que se pueden organizar a través del proceso de registro del Grupo Investor Summit.
Aclarion (Nasdaq: ACON), 만성 요통 진단을 전문으로 하는 헬스케어 기술 회사가 2024년 8월 20일에 열릴 가상 투자 서밋에 참여한다고 발표했습니다. 이 회사는 바이오마커와 독점적인 증강 지능 알고리즘을 활용하여 의사들이 만성 요통의 원인을 찾는 데 도움을 줍니다. 발표는 오후 4시 ET에 진행될 예정입니다.
발표에 참석하고자 하는 투자자는 제공된 웹캐스트 링크를 통해 참여할 수 있습니다. 또한, Aclarion의 경영진과의 개별 미팅 기회도 있으며, 이는 투자 서밋 그룹의 등록 절차를 통해 조정할 수 있습니다.
Aclarion (Nasdaq: ACON), une entreprise de technologie de la santé spécialisée dans le diagnostic de la douleur lombaire chronique, a annoncé sa participation au prochain Virtual Investor Summit qui se tiendra le 20 août 2024. L'entreprise, qui utilise des biomarqueurs et des algorithmes d'intelligence augmentée propriétaires pour aider les médecins à localiser les sources de la douleur lombaire chronique, présentera à 16h00 ET.
Les investisseurs intéressés par la présentation peuvent y accéder via le lien de webdiffusion fourni. De plus, il y a une opportunité pour des séances individuelles avec l'équipe de direction d'Aclarion, qui peuvent être organisées par le biais du processus d'inscription du groupe Investor Summit.
Aclarion (Nasdaq: ACON), ein Unternehmen für Gesundheitstechnologie, das sich auf die Diagnose von chronischen Rückenschmerzen spezialisiert hat, hat seine Teilnahme am kommenden Virtual Investor Summit am 20. August 2024 angekündigt. Das Unternehmen, das Biomarker und proprietäre Algorithmen für augmentierte Intelligenz nutzt, um Ärzten bei der Auffindung von chronischen Rückenschmerzursachen zu helfen, wird um 16:00 Uhr ET präsentieren.
Investoren, die an der Präsentation teilnehmen möchten, können über den bereitgestellten Webcast-Link darauf zugreifen. Darüber hinaus gibt es die Möglichkeit für Einzelgespräche mit dem Management-Team von Aclarion, die über den Registrierungsprozess der Investor Summit Group arrangiert werden können.
- None.
- None.
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20th, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com.
Event: Q3 Investor Summit
Date: August 20, 2024
Presentation Time: 4:00 PM ET
Location: https://www.webcaster4.com/Webcast/Page/3062/51121
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
When is Aclarion (ACON) presenting at the Virtual Investor Summit?
What is the focus of Aclarion's technology?
How can investors attend Aclarion's presentation at the Virtual Investor Summit?
Is it possible to schedule a one-on-one meeting with Aclarion's management?
What is Aclarion's stock symbol?
